We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Celestica's Next-Generation HealthTech Portfolio Lift Its Shares?
Read MoreHide Full Article
Key Takeaways
Celestica provides manufacturing, engineering and supply chain solutions to medical device companies.
CLS' HealthTech portfolio spans imaging systems, surgical equipment, diabetes care and diagnostic products.
CLS supports medical products from initial development through manufacturing and ongoing after-market support.
Celestica Inc. (CLS - Free Report) plays a key role in the healthcare technology sector by providing advanced manufacturing, engineering and supply chain solutions to medical device companies. Its expertise in diagnostics, surgical technologies, patient monitoring and other healthcare applications helps customers bring sophisticated medical products to market.
Celestica’s HealthTech manufacturing portfolio includes medical imaging systems, surgical equipment, diabetes-care devices, in-vitro diagnostic instruments and connected medical products. It provides services such as design and development, precision manufacturing, systems integration and after-market support, helping customers improve product quality, reduce costs and meet regulatory requirements.
The company also uses its global manufacturing footprint and supply chain capabilities to manage complex production needs, improving efficiency, enhancing reliability and supporting the production of highly regulated medical devices. Celestica works with healthcare and medical technology companies across the product lifecycle, from initial development through large-scale manufacturing and ongoing support.
As adoption of digital health solutions, smart medical devices, surgical robotics and advanced diagnostic equipment continues to increase, Celestica is well positioned to benefit from the expanding HealthTech market.
How Are Competitors Advancing in the HealthTech Market?
Celestica faces competition from Jabil, Inc. (JBL - Free Report) and Sanmina Corporation (SANM - Free Report) . Jabil has a broad HealthTech business that supports the development and manufacturing of medical devices and healthcare products. The company is focusing on areas such as connected health, diagnostics, medical equipment and drug-delivery technologies. Jabil’s manufacturing and supply-chain capabilities are helping healthcare companies bring new products to market more efficiently.
Sanmina has a strong presence in HealthTech, providing specialized solutions for medical device manufacturers. Its capabilities span areas such as cardiovascular care, robotic surgery and patient monitoring. Sanmina combines engineering, manufacturing and supply-chain services to support the development and production of medical technologies.
View the Zacks #1 Rank List
Image: Bigstock
Can Celestica's Next-Generation HealthTech Portfolio Lift Its Shares?
Key Takeaways
Celestica Inc. (CLS - Free Report) plays a key role in the healthcare technology sector by providing advanced manufacturing, engineering and supply chain solutions to medical device companies. Its expertise in diagnostics, surgical technologies, patient monitoring and other healthcare applications helps customers bring sophisticated medical products to market.
Celestica’s HealthTech manufacturing portfolio includes medical imaging systems, surgical equipment, diabetes-care devices, in-vitro diagnostic instruments and connected medical products. It provides services such as design and development, precision manufacturing, systems integration and after-market support, helping customers improve product quality, reduce costs and meet regulatory requirements.
The company also uses its global manufacturing footprint and supply chain capabilities to manage complex production needs, improving efficiency, enhancing reliability and supporting the production of highly regulated medical devices. Celestica works with healthcare and medical technology companies across the product lifecycle, from initial development through large-scale manufacturing and ongoing support.
As adoption of digital health solutions, smart medical devices, surgical robotics and advanced diagnostic equipment continues to increase, Celestica is well positioned to benefit from the expanding HealthTech market.
How Are Competitors Advancing in the HealthTech Market?
Celestica faces competition from Jabil, Inc. (JBL - Free Report) and Sanmina Corporation (SANM - Free Report) . Jabil has a broad HealthTech business that supports the development and manufacturing of medical devices and healthcare products. The company is focusing on areas such as connected health, diagnostics, medical equipment and drug-delivery technologies. Jabil’s manufacturing and supply-chain capabilities are helping healthcare companies bring new products to market more efficiently.
Sanmina has a strong presence in HealthTech, providing specialized solutions for medical device manufacturers. Its capabilities span areas such as cardiovascular care, robotic surgery and patient monitoring. Sanmina combines engineering, manufacturing and supply-chain services to support the development and production of medical technologies.
Celestica's Price Performance, Valuation & Estimates
Celestica shares have soared 39.1% over the past year compared with the industry’s growth of 50.1%.
Image Source: Zacks Investment Research
From a valuation standpoint, Celestica trades at a forward price-to-earnings ratio of 20.71, up from the industry average of 19.66.
Image Source: Zacks Investment Research
Earnings estimates for 2026 have increased 11.4% to $11.32 per share over the past 60 days, while the same for 2027 has increased 30.2% to $19.01.
Image Source: Zacks Investment Research
Celestica currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.